期刊
EPIGENETICS
卷 16, 期 6, 页码 642-661出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15592294.2020.1816774
关键词
Cell-free DNA; cell-free RNA; high-risk pregnancy; preeclampsia; gestational diabetes; gestational hypertension
资金
- National Institutes of Health (NIH) [R01HD089714, R01HD00015, U01HD087221]
- National Institutes of Health [R01HD089714, R01HD00015, U01HD087221]
By analyzing the cell-free DNA and RNA content in maternal and cord blood plasma samples, researchers found that these substances may be used to predict adverse pregnancy outcomes early in gestation. They constructed a classifier with a high positive predictive ability for APOs, preeclampsia, and GDM.
Although analysis of maternal plasma cell-free content has been employed for screening of genetic abnormalities within a pregnancy, limited attention has been paid to its use for the detection of adverse pregnancy outcomes (APOs) based on placental function. Here we investigated cell-free DNA and RNA content of 102 maternal and 25 cord plasma samples. Employing a novel deconvolution methodology, we found that during the first trimester, placenta-specific DNA increased prior to the subsequent development of gestational diabetes with no change in patients with preeclampsia while decreasing with maternal obesity. Moreover, using cell-free RNA sequencing, APOs revealed 71 differentially expressed genes early in pregnancy. We noticed the upregulation of S100A8, MS4A3, and MMP8 that have been already associated with APOs but also the upregulation of BCL2L15 and the downregulation of ALPL that have never been associated with APOs. We constructed a classifier with a positive predictive ability (AUC) of 0.91 for APOs, 0.86 for preeclampsia alone and 0.64 for GDM. We conclude that placenta-specific cell-free nucleic acids during early gestation provide the possibility of predicting APOs prior to the emergence of characteristic clinical features.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据